Relationship between nonalcoholic fatty liver disease and liver fibrosis risk scales with overweight and obesity scales in 219,477 spanish workers

• Emilio Martínez-Almoyna Rifá ^[1] ; Pilar Tomás-Gil ^[1] ; Josep Lluis Coll Villalonga ^[1] ; José Ignacio Ramírez-Manent ^{[1] [2]} ; Pau Martí-Lliteras ^[1] ; Ángel Arturo López-González ^[1]
  1. [1] Universitat de les Illes Balears

     Universitat de les Illes Balears

     Palma de Mallorca, España

     
  2. [2] Mallorca Primary Care
• Localización: Academic Journal of Health Sciences: Medicina Balear, ISSN-e 2255-0560, Vol. 38, Nº. 4, 2023, págs. 92-100
• Idioma: inglés
• DOI: 10.3306/AJHS.2023.38.04.92
• Títulos paralelos:
  • Relación entre escalas de riesgo de higado graso no alcohólico y fibrosis hepática con escalas de sobrepeso y obesidad en 219.477 Trabajadores españoles
• Enlaces
  • Texto completo (pdf)
• Resumen
  • español

    Introducción: La Enfermedad del hígado graso no alcohólico (EHGNA) es una patología altamente prevalente y de etiología multifactorial que puede terminar en fibrosis hepática. El objetivo de este estudio es valorar la asociación entre escalas de riesgo de EHGNA y fibrosis hepática y escalas de sobrepeso-obesidad.

    Material y métodos: Estudio descriptivo y transversal en 219477 trabajadores españoles en los que se determina la relación entre los valores de diferentes escalas de riesgo de EHGNA como Fatty liver index (FLI), Hepatic steatosis index (HSI), Zhejian University index (ZJU), Fatty liver disease index (FLD), Framingham steatosis index (FSI), Lipid accumulation Product (LAP) y fibrosis hepática (BARD score) con valores de escalas de sobrepeso-obesidad (índice cintura/altura, índice de masa corporal, Clínica Universitaria de Navarra Estimador de grasa corporal (CUN BAE) y Metabolic Score for Visceral Fat (METS-VF).

    Resultados: Tanto los valores medios como la prevalencia de valores de alto riesgo de presentar EHGNA y fibrosis hepática son más elevados en las personas con obesidad determinados con todas las escalas. Las prevalencias más elevadas se obtienen al aplicar las escalas de BMI y CUN BAE.

    Conclusión: Se confirma la estrecha relación entre los valores de diferentes escalas de riesgo de EHGNA y fibrosis hepática con los valores de escalas de sobrepeso-obesidad.

  • English

    Introduction: Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent pathology of multifactorial etiology that can lead to liver fibrosis. The aim of this study is to assess the association between NASFLD and liver fibrosis risk scales and overweight-obesity scales.

    Material and methods: Descriptive and cross-sectional study in 219477 Spanish workers in which the relationship between the values of different NASH risk scales such as Fatty liver index (FLI), Hepatic steatosis index (HSI), Zhejiang University index (ZJU), Fatty liver disease index (FLD), Framingham steatosis index (Framingham steatosis index), Zhejiang University index (ZJU) and Fatty liver disease index (FLD) was determined, Framingham steatosis index (FSI), Lipid accumulation Product (LAP) and liver fibrosis (BARD score) with values of overweight-obesity scales (waist/height index, body mass index, Clínica Universitaria de Navarra Body Fat Estimator (CUN BAE) and Metabolic Score for Visceral Fat (METS-VF).

    Results: Both the mean values and the prevalence of high-risk values for NASH and liver fibrosis are higher in people with obesity determined with all the scales. The highest prevalences are obtained when applying the BMI and CUN BAE scales.

    Conclusion: The close relationship between the values of different NASH and liver fibrosis risk scales and the values of overweightobesity scales is confirmed.

• Referencias bibliográficas
  • Younossi ZM, Paik JM, Al Shabeeb R, Golabi P, Younossi I, Henry L. Are there outcome differences between NAFLD and metabolicassociated fatty...
  • Nassir F. NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules. 2022 Jun 13;12(6):824. doi: 10.3390/biom12060824.
  • Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, et al. Advancing the global public health agenda for NAFLD: a consensus statement....
  • Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany,...
  • Morrow MR, Batchuluun B, Wu J, Ahmadi E, Leroux JM, Mohammadi- Shemirani P, et al. Inhibition of ATP-citrate lyase improves NASH, liver fibrosis,...
  • Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical...
  • Vilalta A, Gutiérrez JA, Chaves S, Hernández M, Urbina S, Hompesch M. Adipose tissue measurement in clinical research for obesity, type 2...
  • Chen Y, Ma L, Ge Z, Pan Y, Xie L. Key Genes Associated With Non- Alcoholic Fatty Liver Disease and Polycystic Ovary Syndrome. Front Mol Biosci....
  • Stefan N, Cusi K. A global view of the interplay between nonalcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022 Apr;10(4):284-296....
  • Hatziagelaki E, Paschou SA, Schön M, Pshighpoulou T, Roden M. NAFLD and thyroid function: pathophysiological and therapeutic considerations....
  • Huang Q, Xu H, Wang X, Mao J, Yu B, Zhu Y, et al. Relationship between growth hormone deficiency and nonalcoholic fatty liver disease in patients...
  • Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review...
  • Siwarom S, Pirojsakul K, Aekplakorn W, Paksi W, Kessomboon P, Neelapaichit N, et al. Waist-to-Height Ratio Is a Good Predictor of Metabolic...
  • López-González AA, Jover AM, Martínez CS, Artal PM, Bote SA, Jané BA, et al. The CUN-BAE, Deurenberg Fat Mass, and visceral adiposity index...
  • Bello-Chavolla OY, Antonio-Villa NE, Vargas-Vázquez A, Viveros- Ruiz TL, Almeda-Valdes P, Gomez-Velasco D, et al. Metabolic Score for Visceral...
  • Bello-Chavolla OY, Almeda-Valdes P, Gomez-Velasco D, Viveros- Ruiz T, Cruz-Bautista I, Romo-Romo A, et al. METS-IR, a novel score to evaluate...
  • Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of...
  • Wang C, Cai Z, Deng X, Li H, Zhao Z, Guo C, et al. Association of Hepatic Steatosis Index and Fatty Liver Index with Carotid Atherosclerosis in...
  • Li L, You W, Ren W. The ZJU index is a powerful index for identifying NAFLD in the general Chinese population. Acta Diabetol. 2017 Oct;54(10):905-911....
  • Lee I, Cho J, Park J, Kang H. Association of hand-grip strength and non-alcoholic fatty liver disease index in older adults. J Exerc Nutrition Biochem....
  • Long MT, Pedley A, Colantonio LD, Massaro JM, Hoffmann U, Muntner P, et al. Development and Validation of the Framingham Steatosis Index to...
  • Sheng G, Lu S, Xie Q, Peng N, Kuang M, Zou Y. The usefulness of obesity and lipid-related indices to predict the presence of Nonalcoholic fatty...
  • Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis...
  • Domingo-Salvany A, Bacigalupe A, Carrasco JM, Espelt A, Ferrando J, Borrell C; del Grupo de Determinantes Sociales de Sociage Española de...
  • Liu Z, Zhang Y, Graham S, Wang X, Cai D, Huang M, et al. Causal relationships between NAFLD, T2D and obesity have implications for disease...
  • Milić S, Lulić D, Štimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol....